Last Updated: November 19, 2026

Details for Patent: 6,610,327

« Back to Dashboard


Summary for Patent: 6,610,327
Title:Pharmaceutical moxifloxacin preparation
Abstract:The present invention relates to a pharmaceutical preparation for oral administration which comprises moxifloxacin, its salt and/or hydrate and lactose, to a process for its preparation, and to the use of this preparation for controlling bacterial infections in humans and animals.
Inventor(s):Patrick Bosché, Hans Friedrich Mahler, Claus Weisemann
Assignee: Bayer Intellectual Property GmbH
Application Number:US09/830,770
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;
Patent landscape, scope, and claims:

United States Patent 6,610,327: Claim Scope, Expiration, Orange Book Status, and Moxifloxacin Patent Landscape

U.S. Patent No. 6,610,327 protected oral moxifloxacin formulations containing lactose, a dry binder, a disintegrant, and a lubricant. The patent also covered specified tablet compositions, film-coated tablets, wet-granulation processing, and treatment of bacterial infections using the claimed preparation. The patent was assigned to Bayer and has reached the end of its statutory patent term. It no longer creates a current U.S. blocking right against generic moxifloxacin tablets.

What does U.S. Patent 6,610,327 cover?

The patent covers a formulation platform rather than the moxifloxacin molecule itself. Its central limitation is a solid oral preparation containing:

  • Moxifloxacin or a salt or hydrate;
  • At least one dry binder;
  • At least one disintegrant;
  • At least one lubricant; and
  • Lactose in an amount from 2.5% to 25%.

The claims use the transitional term “comprises.” That wording generally makes the claims open-ended. A product can contain additional excipients and still fall within the claim if it contains every required element and satisfies the stated quantitative limitations.

Claim-by-claim scope

Claim Subject matter Principal limitations
1 Oral pharmaceutical preparation Moxifloxacin or salt/hydrate; dry binder; disintegrant; lubricant; lactose at 2.5%-25%
2 Preparation of claim 1 50-800 mg moxifloxacin or derivative per dosage unit
3 Preparation of claim 1 or 2 Dry binder is microcrystalline cellulose
4 Preparation of claim 1 Disintegrant is croscarmellose sodium
5 Preparation of claim 1 Lubricant is magnesium stearate
6 Composition 60%-76% moxifloxacin; 7.5%-16% lactose; 2%-6% croscarmellose sodium; 0.5%-1.1% magnesium stearate; up to 30% microcrystalline cellulose
7 Tablet Core of claim 1 with a film coating
8 Preparation of claim 1 Moxifloxacin hydrochloride
9 Manufacturing process Moxifloxacin, dry binder and lactose granulated with water, followed by mixing with disintegrant and lubricant
10 Treatment method Treating bacterial infection by administering the claim 1 preparation

The independent composition claim is claim 1. Claim 9 is an independent process claim, and claim 10 is an independent method-of-treatment claim.

How strong is the patent estate for moxifloxacin tablets?

The patent estate was commercially important during the period when Bayer’s Avelox oral tablets were protected. Its strength came from combining a common active ingredient with a defined excipient architecture and a manufacturing sequence.

The central formulation is consistent with the inactive-ingredient profile used for moxifloxacin hydrochloride tablets, including lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The patent did not claim every moxifloxacin tablet. It required the lactose range and the specified functional excipient categories.

Technical scope of the formulation

Claim 1 reaches formulations with broad excipient identity requirements but a relatively narrow lactose range:

  • Less than 2.5% lactose falls outside the express lactose limitation.
  • More than 25% lactose also falls outside the express range.
  • The claim requires a dry binder, disintegrant, and lubricant.
  • The claim does not require microcrystalline cellulose, croscarmellose sodium, or magnesium stearate unless the narrower dependent claims are asserted.
  • The claim does not require a film coating.
  • The claim does not require wet granulation.

This structure gave the patent multiple infringement theories. A tablet could potentially infringe claim 1 without infringing claim 9 if the manufacturing process used direct compression rather than aqueous granulation. Conversely, evidence of the manufacturing process would be relevant only to process claim 9.

Claim 6 is the narrowest commercial composition claim

Claim 6 describes a commercially recognizable moxifloxacin tablet composition:

  • 60%-76% moxifloxacin or salt/hydrate;
  • 7.5%-16% lactose;
  • 2%-6% croscarmellose sodium;
  • 0.5%-1.1% magnesium stearate; and
  • Up to 30% microcrystalline cellulose.

Because claim 6 depends on claim 1, the product must also satisfy the broader claim 1 requirements. The “up to 30%” limitation for microcrystalline cellulose does not require the presence of that excipient. Claim 3, by contrast, requires microcrystalline cellulose as the dry binder.

The percentage limitations create potential design-around opportunities. A manufacturer could alter lactose concentration, replace lactose with another filler, change the disintegrant or lubricant, or use a different granulation sequence. Whether such changes avoid infringement depends on the final formulation, claim construction, and the doctrine of equivalents.

What formulations are protected by U.S. Patent 6,610,327?

The patent protects oral solid preparations, especially tablets, that use lactose as part of a moxifloxacin formulation containing standard tableting excipients.

Protected formulation combinations

The strongest literal-infringement scenario would involve a tablet containing:

  • Moxifloxacin hydrochloride;
  • Lactose within the 2.5%-25% range;
  • Microcrystalline cellulose;
  • Croscarmellose sodium;
  • Magnesium stearate; and
  • A dosage amount within the 50-800 mg range.

A film-coated version would implicate claim 7. A formulation containing the claim 6 percentage ranges would present a narrower but more specific claim exposure.

Formulations outside the principal claim

The following products would generally fall outside the literal scope of claim 1 if the stated facts were established:

  1. A lactose-free moxifloxacin tablet.
  2. A tablet with lactose below 2.5% or above 25%.
  3. A product lacking a dry binder, disintegrant, or lubricant.
  4. An oral liquid or injectable preparation.
  5. A product containing moxifloxacin but not the claimed oral pharmaceutical preparation.
  6. A tablet made without the aqueous granulation sequence required by claim 9.

The use of a different filler does not automatically avoid infringement if lactose remains within the claimed range. Because the claim is open-ended, additional excipients are permitted.

When did U.S. Patent 6,610,327 lose exclusivity?

U.S. Patent 6,610,327 issued on August 26, 2003. Its ordinary patent term ran from the relevant U.S. nonprovisional filing date, subject to any patent-term adjustment or extension recorded by the USPTO. Public patent records place the effective patent term in 2019, and the patent is no longer an enforceable blocking patent for current U.S. generic entry. [1]

The patent did not provide biologic exclusivity. Moxifloxacin is a small-molecule antibacterial, and generic applicants use the abbreviated new drug application pathway rather than the biosimilar pathway.

Exclusivity timeline

Event Date or period
Priority and patent-family development 1998-era priority filings
U.S. patent application Before issuance in 2003
U.S. Patent 6,610,327 issued August 26, 2003
Commercial relevance Avelox oral tablet lifecycle
Statutory patent term Ended in 2019, subject to recorded term adjustments
Current blocking effect None after expiration

FDA regulatory exclusivity and patent exclusivity are separate. Any five-year new chemical entity exclusivity associated with the original moxifloxacin approval would have expired years before the formulation patent. The relevant commercial protection later depended primarily on patents and regulatory approval status rather than current FDA exclusivity. [2]

What is the Orange Book status of U.S. Patent 6,610,327?

The patent was associated with the U.S. moxifloxacin tablet product marketed as Avelox by Bayer. The FDA Orange Book has historically identified patent information for approved drug products, including patent listings relevant to generic applicants. [2]

An Orange Book listing does not establish validity or infringement. It gives an ANDA applicant a potential basis for a Paragraph IV certification if the applicant contends that the patent is invalid, unenforceable, or not infringed.

Because U.S. Patent 6,610,327 has expired, it no longer supports a current Paragraph IV-based delay of generic approval. A historical Paragraph IV challenge could have been relevant before expiration, but the patent’s expiration removed the practical value of continued enforcement.

Which companies challenged moxifloxacin patent protection?

Generic moxifloxacin competition involved major generic manufacturers seeking approval for moxifloxacin hydrochloride tablets. Public FDA records and patent litigation databases should be used to identify the complete set of historical Paragraph IV filers and defendants for each Avelox patent.

The relevant competitive group included companies such as Teva, Sandoz, Mylan, and other ANDA sponsors active in the U.S. fluoroquinolone market. The litigation risk depended on which patent was challenged, the ANDA formulation, the certification date, and whether the brand company filed suit within the statutory 45-day period.

A Paragraph IV certification would not necessarily challenge only U.S. Patent 6,610,327. Moxifloxacin applicants could also face molecule, crystalline-form, formulation, process, or method-of-use patents listed against the reference product.

What patent litigation affects U.S. Patent 6,610,327?

The principal legal issues for this patent would have been:

  • Whether the accused tablet contained lactose within the claimed percentage range;
  • Whether the formulation used a qualifying dry binder;
  • Whether the disintegrant and lubricant limitations were met;
  • Whether the claimed dosage amount was present per individual dosage;
  • Whether a film coating covered a core meeting claim 1;
  • Whether the accused process used aqueous granulation in the sequence required by claim 9;
  • Whether the method-of-treatment claim was enforceable against an ANDA applicant; and
  • Whether the patent was invalid for anticipation or obviousness.

Formulation patents often face obviousness challenges based on routine selection of excipients and known tablet-manufacturing methods. The patentee’s position would depend on evidence that the particular lactose range and excipient combination produced unexpected stability, dissolution, manufacturability, bioavailability, or other technical results.

Settlement agreements

A settlement involving a Paragraph IV challenge could have included a licensed entry date, a covenant not to sue, or a commercially agreed launch date. Expiration of the patent now controls the maximum exclusion period. No current market exclusion can be based solely on U.S. Patent 6,610,327.

What generic entry risks exist for moxifloxacin tablets?

The patent-specific risk is now low because the patent has expired. Current generic entry risks are more likely to involve:

  • FDA approval requirements;
  • Bioequivalence and dissolution performance;
  • Product-quality compliance;
  • Labeling and therapeutic-substitution issues;
  • Manufacturing capacity;
  • Supply-chain economics; and
  • Any separate, later-issued patent covering a particular product, delivery system, or manufacturing process.

For a historical ANDA applicant, the highest risk would have been a formulation that closely reproduced the Avelox tablet composition. A lactose-free formulation or a composition outside the claimed ranges would have reduced literal-infringement risk, although it could have introduced development or bioequivalence challenges.

How does this patent compare with the moxifloxacin molecule patent?

U.S. Patent 6,610,327 should be distinguished from patents claiming moxifloxacin itself or its broader pharmaceutical use.

Patent category Subject matter Commercial effect
Compound patent Moxifloxacin molecule and related chemical subject matter Broadest early protection
Formulation patent Lactose-containing oral preparations with specified excipients Product-specific protection
Process patent Aqueous granulation and subsequent blending Manufacturing-process protection
Method patent Treating bacterial infection with the claimed formulation Use-based protection
Regulatory exclusivity FDA approval-based protection Separate from patent term

The formulation patent was narrower than a valid compound patent. Once compound and formulation patents expired, generic manufacturers could seek approval for moxifloxacin tablets subject to FDA requirements.

Does the patent create biosimilar risk?

No. Moxifloxacin is a synthetic small-molecule drug, not a biologic. The relevant competitors are generic-drug applicants under the ANDA pathway, not biosimilar applicants under the Public Health Service Act.

What is the geographic coverage of the patent estate?

U.S. Patent 6,610,327 protected the claimed subject matter only in the United States. Corresponding applications or patents may have existed in Europe and other jurisdictions through the same international patent family, but foreign rights required separate analysis of:

  • National filing dates;
  • Local claim scope;
  • Patent-term adjustments;
  • Supplementary protection certificates;
  • Opposition proceedings;
  • Local validity decisions; and
  • Country-specific expiration dates.

U.S. expiration did not automatically terminate corresponding foreign rights. It also did not create any continuing U.S. right after expiration.

Key Takeaways

  • U.S. Patent 6,610,327 covers oral moxifloxacin preparations containing lactose at 2.5%-25%, plus a dry binder, disintegrant, and lubricant.
  • Claims 2-8 narrow the dosage, excipient identities, composition, coating, and moxifloxacin hydrochloride form.
  • Claim 9 covers a specific aqueous-granulation process.
  • Claim 10 covers treatment of bacterial infection using the claimed preparation.
  • Claim 6 targets a commercially recognizable moxifloxacin hydrochloride tablet composition.
  • The patent issued on August 26, 2003 and reached the end of its statutory term in 2019.
  • The patent is no longer a current U.S. barrier to generic moxifloxacin tablet entry.
  • Moxifloxacin is a small molecule, so biosimilar analysis is inapplicable.
  • Historical Paragraph IV challenges could have targeted this patent and other Avelox-related patents.
  • Current commercial exposure depends on generic competition, FDA compliance, manufacturing economics, and any separate surviving rights, not on this expired patent.

FAQs

Is U.S. Patent 6,610,327 a compound patent for moxifloxacin?

No. It is a formulation, manufacturing-process, and treatment-method patent. It does not broadly claim the moxifloxacin molecule itself.

Does a lactose-free moxifloxacin tablet infringe Patent 6,610,327?

A lactose-free tablet would not literally satisfy the lactose limitation in claim 1. Separate infringement theories would require analysis of other claims and the doctrine of equivalents.

Does claim 9 cover every method of making a moxifloxacin tablet?

No. Claim 9 requires aqueous granulation of moxifloxacin, a dry binder, and lactose, followed by mixing the granules with a disintegrant and lubricant.

Could a generic manufacturer use a different disintegrant?

Yes, a different disintegrant could avoid dependent claim 4, but claim 1 still requires at least one disintegrant. The substitute must be assessed against the claim language and any equivalents theory.

Can an expired formulation patent still block FDA approval?

An expired patent cannot provide a current patent-based exclusion period. FDA approval may still depend on bioequivalence, manufacturing, labeling, safety, and other regulatory requirements.

References

  1. United States Patent and Trademark Office. (2003). U.S. Patent No. 6,610,327, Pharmaceutical preparations containing moxifloxacin.
  2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
  3. U.S. Food and Drug Administration. (n.d.). Approved drug product labeling: Avelox (moxifloxacin hydrochloride).
  4. United States Code, 35 U.S.C. §§ 154, 271, 282.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 6,610,327

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,610,327

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany198 55 758Nov 10, 1998
PCT Information
PCT FiledOctober 29, 1999PCT Application Number:PCT/EP99/08230
PCT Publication Date:May 18, 2000PCT Publication Number: WO00/27398

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.